• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Extended-Release Guanfacine Improves ADHD Symptoms in Autism

Extended-Release Guanfacine Improves ADHD Symptoms in Autism

July 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Bret A. Moore, PsyD, ABPP. Board-Certified Clinical Psychologist, San Antonio, TX. Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Subject:
(Scahill S et al, Am J Psychiatry 2016;172:1197–1206)

Short Description:

Children with autism spectrum disorder (ASD) often have symptoms of ADHD. While it’s not always easy to distinguish them from the core features of autism, symptoms such as impulsivity, hyperactivity, and distractibility do occur, and we often use medications to target them. Stimulants are fairly effective but tend to cause more side effects in autistic ADHD kids than in children with pure ADHD. Atomoxetine was only equivocally effective in one trial, and the immediate-release version of guanfacine was tested in a small open-label trial, resulting in improvement in about half the subjects.

Recognizing the need for more data, researchers conducted the first ever randomized placebo-controlled trial of guanfacine in ASD/ADHD, in this case using the extended-release (ER) version. Children between the ages of 5 and 14 with a diagnosis of ASD with accompanying impulsivity, hyperactivity, and distractibility were randomly assigned to either ER guanfacine (n = 30) or placebo (n = 32). During this 8-week trial, ER guanfacine was started at 1 mg once a day for all children. Depending on the child’s weight and response, a maximum of 4 mg daily could be prescribed. The primary outcome measure was change from baseline on the parent version of the Aberrant Behavior Checklist (ABC) hyperactivity subscale, which was assessed at weeks 4, 6, and 8. The Clinical Global Impression-Improvement (CGI-I) scale was also used.

ER guanfacine was effective. At the end of 8 weeks, the medication group showed a 44% reduction in scores on the ABC hyperactivity subscale compared to 13% for the placebo group. For the ER guanfacine group, half were rated “much improved” or “very much improved” on the CGI-I, whereas fewer than 10% of the placebo group were so rated. Significant improvements were seen in both hyperactivity and inattention vs. placebo. The most frequently prescribed dose in both groups was 3 mg. Overall, ER guanfacine was well tolerated. The most common complaints were drowsiness, fatigue, and loss of appetite. Drops in blood pressure and heart rate from baseline were seen in the guanfacine group. Blood pressure normalized by the end of 8 weeks, but heart rate did not, remaining about 10 points below baseline. This effect was not considered clinically significant.

CCPR’s Take: This was a small study of short duration, but the results were promising. When using ER guanfacine, start with 1 mg in the morning and titrate up slowly as needed. Dose it in the evening if the child becomes drowsy. By the way, ER guanfacine is now available as a cheap generic, so don’t feel guilty prescribing it. On the other hand, the ER version’s duration of action is only marginally longer than the IR version (about 24 hours vs. about 17 hours) so you don’t gain much by choosing it.

Child Psychiatry
KEYWORDS autism-spectrum-disorder child-psychiatry psychopharmacology_tips
Bret a moore psyd abpp
Bret A. Moore, PsyD, ABPP

Psychedelic Mushrooms May Help Treatment Resistant Depression

More from this author
www.thecarlatreport.com
Issue Date: July 1, 2016
SUBSCRIBE NOW
Table Of Contents
Treating Disruptive Behavior Disorders in Children
Evolution of Childhood Bipolar Disorder in the United States
Atomoxetine Does Not Increase Risk of Suicide Compared to Stimulants
Extended-Release Guanfacine Improves ADHD Symptoms in Autism
Disruptive Mood Dysregulation Disorder: A Primer
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.